[1] 谭业颖,田嘉禾,张锦明,等.18F-FLT PET显像诊断肺单发结节及评价细胞增殖的价值.中华核医学杂志,2007,48(2):65.
[2] Yap CS, Czernin J, Fishbein MC, et al. Evaluation of thoracic tumors with 18F-fluorothymitine and 18F-fluorodeoxyglueosepositron emission tomography. Chest, 2006, 129(2):393-401.
[3] van Waarde A, Cobben DC, Suunneijer A J, et al. Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model. J Nucl Med, 2004, 45(4):695-700.
[4] Yavuamuto Y, Nishiyama Y, Ishikawa S, et al. Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer. Eur J Nucl Med Mol Imaging, 2007, 34(10):1610-1616.
[5] Buck AK, Halter G, Schimneisler H, et al. Imaging proliferation in lung tumors with PET:18F-FLT versus 18F-FDG. J Nucl Med, 2003, 44(9):1426-14317.
[6] Mankoff DA, Shields AF, Krohu KA. PET imaging of cellular proliferation. Radiol Clin North Am, 2005, 43(1):153-167.
[7] 柳曦,周乃康,张锦明,等.18F-FLT摄取与肺癌细胞增殖的相关性.癌症,2006,25(12):1512-1516.
[8] Bading JR, Shiehts AF. Imaging of cell proliteration:status and prospects. J Nucl Med, 2008, 49(Suppl 2):64S-80S.
[9] Sugiyama M, Sakahara H, Sato K, et al. Evaluation of 3'-deoxy-3'-18F-fluorothymidine for monitoring tumor response to radiotherapy and photodynamic therapy in mice. J Nucl Med, 2004, 45(10):1754-1758.
[10] Barthcl H, Cleij MC, Collingridge DR, et al. 3'-deoxy-3'-[18F] fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res, 2003, 63(13):3791-3798.
[11] Shields AF, Mankoff DA, Link JN, et al. Carbon-11-thymidine and FDG to measure therapy response. J Nucl Med, 1998, 39(10):1757-1762.
[12] Reinhardt M J, Kubota K, Yamada S, et al. Assessment of cancer recurrence in residual tumors after fractionated radiotherapy:a comparison of fluorodeoxyglucose, L-methionine and thymidine. J Nucl Med, 1997, 38(2):280-287.
[13] Rasey JS, Grierson JR, Wiens LW, et al. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med, 2002, 43(9):1210-1217.
[14] 柳曦,周乃康,张锦明,等.18F-FLT在肺癌模型小鼠体内的生物分布及PET显像研究.解放军医学杂志,2006,31(10):960-962.
[15] 魏荣卿,Machulla HJ,刘晓宁.检测肿瘤增殖的显像剂18F-FLT.中华核医学杂志,2005,25(1):59-61.
[16] Been LB, Suumeijer AJ, Cobben DC, et al.[18F] FLT-PET in oncology:current status and opportunities. Eur J Nucl Med Mol Imaging, 2004, 31(12):1659-1672.
[17] Dittmann H, Dohmen BM, Kehlbaeh R, et al. Early changes in[18F] FLT uptake after chemotherapy:an experimental study. Eur J Nucl Med Mol Imaging, 2002, 29(11):1462-1469.
[18] Apisanthanarax S, Alauddin MM, Mourtada F, et al. Early detection of chemoradioresponse in esophageal carcinoma by 3'-deoxy-3'-3H-fluorothymidine using preclinical tumor models. Clin Cancer Res, 2006; 12(15):4590-4597.
[19] Chao KS. Functional imaging for early prediction of response to chemoradiotherapy:3'-deoxy-3'-18F-fluorothymidine position emission tomography-a clinical application model of esophageal cancer. Semin Oncol, 2006, 33(6 Suppl 11):S59-S63.
[20] 柳曦,.PET示踪剂18F-FLT在肿瘤学中的研究进展.第三军医大学学报,2006,28(12):1351-1353.
[21] 张锦明,朱虹,姚树林,等.18F-FDG和18F-FLT早期检测肺癌放疗、化疗疗效的实验研究.中国医学影像技术研究会第六次全圉会员代表大会暨第二十二次学术大会论文汇编,北京.2008:238-239.
[22] Sohn HJ, Yang YJ, Ryu JS, et al.[18F]Fluorothymidine positron emission tomography before and 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung. Clin Cancer Res, 2008, 14(22):7423-7429.
[23] Dohmen BM, Shiehts AF, Dittmann H, et al. Use of[18F]FLT for breast cancer imaging. J Nucl Med, 2001, 41(Suppl):29.
[24] Pio BS, Park CK, Pietras R, et al. Usefulness of 3'-[F-18]fluoro-3'-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol, 2006, 8(1):36-42.
[25] Direcks WG, van Gelder M, Lammertsma AA, et al. A new rat model of human breast cancer for evaluating efficacy of new anti-cancer agents in vivo. Cancer Biol Ther, 2008, 7(4):532-537.
[26] Direcks WG, Berndsen SC, Prnost N, et al.[18F]FDG and[18F]FLT uptake in human breast cancer cells in relation to the effects of chemotherapy:an in vitro study. Br J Cancer, 2008, 99(3):481-487.
[27] Pan MH, Huang SC, Liao YP, et al. FLT-PET imaging of radiation responses in murine tumors. Mol Imaging Biol, 2008, 10(6):325-334.
[28] Kumar A, Kumar R, Seenu V, et al. The role of 18F-FDG PET/CT in evaluation of early response to nenadjuvant chemotherapy in patients with locally advanced breast cancer. Eur Radiol, 2009, 19(6):1347-1357.
[29] Dittmann H, Jusufoska A, Dohmen BM, et al. 3'-Deoxy-3'-[18F] fluorothymidine (FLT) uptake in breast cancer cells as a measure of proliteration after doxorubicin and docetaxel treatment. Nucl Med Biol, 2009, 36(2):163-169.
[30] Buck AK, Pitterle K, Schirrmeister H, el al.[18F] FLT positron emission tomography for imaging non-Hodgkin's lymphoma and assessment of proliferative activity. J Nucl Med, 2003, 44(2):188-189.
[31] Buck AK, Kratochwil C, Glatting G, et al. Early assessment of therapy response in malignant lymphoma with the thymidine analogue[18F]FLT. Eur J Nucl Med Mol Imaging, 2007, 34(11):1775-1182.
[32] Herrmann K, Wieder HA, Buek AK, et al. Early response assessment using 3'-deoxy-3'[18F]fluorothymidine-positrnn emission tomography in high-grade non-Hodgkin's lymphoma. Clin Cancer Res, 2007, 13(12):3552-3558.
[33] Graf N, Herrmann K, den Hollander J, et al. Imaging proliferation to monitor early response of iymphoma to cytotoxic treatment. Mol Imaging Biol, 2008, 10(6):349-355.
[34] Murayama C, Harada N, Kakiuehi T, et al. Evaluation of D-18F-FMT, 18F-FDG, L-11C-MET, and 18F-FLT for monitoring the response of tumors to radiotherapy in mice. J Nucl Med, 2009, 50(2):290-295.
[35] Wieder HA, Geinitz H, Rosenberg R, et al. PET imaging with 3-[F-18]-fluoro-3-deoxythymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer. Eur J Nucl Med Mol Imaging, 2007, 34(6):878-883.
[36] Oyama N, Ponde DE, Dence C, et al. Monitoring of therapy in androgen-dependent prostate tumor model by measuring tumor proliferation. J Nucl Med, 2004, 45(3):519-525.